Drug Type Bispecific antibody |
Synonyms CN 202, CN-202 |
Target |
Mechanism PDL1 inhibitors(Programmed death-ligand 1 inhibitors), TGF-β inhibitors(Transforming growth factor beta inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hematologic Neoplasms | Phase 2 | - | 22 Oct 2021 | |
Locally Advanced Malignant Solid Neoplasm | Phase 2 | - | 22 Oct 2021 | |
Metastatic Solid Tumor | Phase 2 | - | 22 Oct 2021 | |
Solid tumor | IND Approval | CN | 04 Nov 2021 |